RT Journal Article
SR Electronic
T1 Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.03.24312664
DO 10.1101/2024.09.03.24312664
A1 Joynes, Cassandra M.
A1 Bilgel, Murat
A1 An, Yang
A1 Moghekar, Abhay R.
A1 Ashton, Nicholas J.
A1 Kac, Przemysław R.
A1 Karikari, Thomas K.
A1 Blennow, Kaj
A1 Zetterberg, Henrik
A1 Thambisetty, Madhav
A1 Ferrucci, Luigi
A1 Resnick, Susan M.
A1 Walker, Keenan A.
YR 2024
UL http://medrxiv.org/content/early/2024/09/04/2024.09.03.24312664.abstract
AB INTRODUCTION The factors that influence the progression of Alzheimer’s disease (AD) after individuals become amyloid-positive are poorly understood. This study examines how sex influences the longitudinal trajectories of plasma AD and neurodegenerative biomarkers in the years following a person’s estimated onset of amyloid-β.METHODS Linear mixed effects modeling investigated overall and sex-specific longitudinal trajectories of plasma biomarkers, brain volumes, and cognition relative to estimated age of amyloid onset in a cohort of 78 amyloid-positive Baltimore Longitudinal Study of Aging participants (n=45 male; follow-up time: 6.8 years [SD 3.31]). Amyloid status was ascertained with 11C-Pittsburgh compound B (PiB) PET imaging.RESULTS After amyloid onset, men displayed steeper increases in pTau181, pTau231, and NfL compared to women. In this same period, men demonstrated steeper declines in brain volume and cognitive performance.DISCUSSION These findings suggest that sex influences the trajectory of AD pathology, neuronal injury, and symptom progression after individuals become amyloid-positive.Competing Interest StatementHZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).Funding StatementThis study was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (AG000349-01). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Baltimore Longitudinal Study of Aging (BLSA) research protocols were conducted in accordance with United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by local institutional review boards (IRB), and all participants gave written informed consent at each visit. The BLSA PET substudy is governed by the IRB of the Johns Hopkins Medical Institutions, and the BLSA study is overseen by the National Institute of Environmental Health Sciences IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBLSA data are available upon request from https://www.blsa.nih.gov. All requests are reviewed by the BLSA Data Sharing Proposal Review Committee. https://www.blsa.nih.gov